デフォルト表紙
市場調査レポート
商品コード
1496205

がん免疫療法市場:2024-2034年

Cancer Immunotherapy Market Report 2024-2034

出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 286 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=206.60円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

がん免疫療法市場:2024-2034年
出版日: 2024年06月12日
発行: Visiongain Reports Ltd.
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん免疫療法の市場規模は、2034年にかけてCAGR 12.6%で成長すると予測されています。

癌罹患率の増加とがん免疫療法研究の増加が市場成長を牽引:

世界保健機関 (WHO) が2024年2月に発表したデータによると、癌は世界の主要死因であり、2022年には約2,000万人が新たに癌に罹患し、900万人以上が死亡しています。2040年までには、人口の高齢化と増加により、世界の癌患者数は2,800万人を超えると米国癌協会 (American Cancer Society, Inc.) は予測しています。北米は癌死亡者数で4位、新規症例数で4位であるのに対し、世界最大の人口を抱える中国は、両方の割合が世界で最も高いです。世界各地でアルコールやタバコの使用量が増え、食生活が乱れ、運動不足になり、大気汚染が進むなどの要因により、癌の負担は今後増加する可能性があります。

免疫療法に代表される最新の癌治療は、近年この分野に革命をもたらしました。研究者や腫瘍学者を大いに興奮させている治療法のひとつががん免疫療法です。長年にわたる集中的な研究の結果、がん免疫療法が癌の治療法として世界的に用いられるようになっています。例えば、ドイツの生物医学研究機関であるBioMed Xと日本最大手の製薬会社である小野薬品工業は、2023年12月に新たな共同研究の開始を発表しました。好中球の抗癌作用を利用して次世代の免疫療法を開発することが、この研究の目的です。これらのことから、同市場の成長を促進する主な要因は、免疫療法を改善する手法に関する継続的な研究と、癌治療のための新規免疫療法の継続的な開発です。

当レポートでは、世界のがん免疫療法の市場を調査し、市場概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
  • 影響分析
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • サプライチェーン分析
  • 規制の枠組み
  • 新興市場とメガトレンド
  • ポーターのファイブフォース分析
  • PEST分析

第4章 がん免疫療法市場の分析:技術別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • モノクローナル抗体
  • 免疫調節薬
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第5章 がん免疫療法市場の分析:用途別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 肺癌
  • 乳癌
  • 大腸癌
  • 悪性黒色腫
  • 前立腺癌
  • 頭頸部癌
  • 卵巣癌
  • 膵臓癌
  • その他
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第6章 がん免疫療法市場の分析:エンドユーザー別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 病院
  • 癌研究センター
  • クリニック
    • 市場規模の推移・予測:地域別
    • 市場シェア:地域別

第7章 がん免疫療法市場の分析:地域別

  • 主要調査結果
  • 市場規模の推移・予測

第8章 北米のがん免疫療法市場の分析

第9章 欧州のがん免疫療法市場の分析

第10章 アジア太平洋のがん免疫療法市場の分析

第11章 ラテンアメリカのがん免疫療法市場の分析

第12章 中東・アフリカのがん免疫療法市場の分析

第13章 企業プロファイル

  • 競合情勢
  • 戦略的展望
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co., Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Bayer AG
  • AstraZeneca
  • Lilly
  • Pfizer Inc.
  • Johnson &Johnson Services, Inc.
  • GSK plc
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Immunocore Ltd.
  • Sanofi
  • Takeda Pharmaceutical Company Limited.

第14章 総論・提言

  • Visiongainによる総論
  • 市場参入企業への提言
図表

List of Tables

  • Table 1 Cancer Immunotherapy Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
  • Table 2 Cancer Immunotherapy Market Forecast by Technology 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 3 Types of Monoclonal Antibodies
  • Table 4 Types of Monoclonal Antibodies and Approval Status
  • Table 5 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 6 Immunomodulators Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 7 Other Technology Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 8 Cancer Immunotherapy Market by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 9 Types of Monoclonal Antibodies
  • Table 10 Lung Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 11 Breast Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 12 Colorectal Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 13 Melanoma Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 14 Prostate Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 15 Head & Neck Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 16 Ovarian Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 17 Pancreatic Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 18 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 19 Cancer Immunotherapy Market by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 20 Hospitals Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 21 Cancer Research Centers Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 22 Clinics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 23 Cancer Immunotherapy Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 24 North America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 25 North America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 26 North America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 27 North America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 28 U.S. Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 29 Canada Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 30 Europe Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 31 Europe Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 32 Europe Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 33 Europe Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 34 Germany Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 35 UK Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 36 France Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 37 Italy Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 38 Spain Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 39 Switzerland Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 40 Netherlands Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 41 Rest of Europe Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 42 Asia Pacific Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 43 Asia Pacific Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 44 Asia Pacific Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 45 Asia Pacific Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 46 Japan Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 47 China Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 48 India Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 49 Australia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 50 South Korea Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 51 South East Asia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 52 Rest of Asia Pacific Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 53 Latin America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 54 Latin America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 55 Latin America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 56 Latin America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 57 Brazil Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 58 Mexico Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 59 Argentina Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 60 Rest of Latin America Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 61 MEA Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 62 MEA Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 63 MEA Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 64 MEA Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 65 GCC Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 66 South Africa Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 67 Egypt Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 68 Rest of MEA Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 69 Strategic Outlook
  • Table 70 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 71 F. Hoffmann-La Roche Ltd. : Product Benchmarking
  • Table 72 F. Hoffmann-La Roche Ltd.: Strategic Outlook
  • Table 73 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 74 Merck & Co., Inc.: Product Benchmarking
  • Table 75 Merck & Co., Inc.: Strategic Outlook
  • Table 76 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 77 Novartis AG: Product Benchmarking
  • Table 78 Novartis AG: Strategic Outlook
  • Table 79 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 80 Bristol-Myers Squibb Company: Product Benchmarking
  • Table 81 Bristol-Myers Squibb Company: Strategic Outlook
  • Table 82 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Bayer AG: Product Benchmarking
  • Table 84 Bayer AG: Strategic Outlook
  • Table 85 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 AstraZeneca: Product Benchmarking
  • Table 87 AstraZeneca: Strategic Outlook
  • Table 88 Lilly.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Lilly.: Product Benchmarking
  • Table 90 Lilly: Strategic Outlook
  • Table 91 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Pfizer Inc.: Product Benchmarking
  • Table 93 Pfizer Inc.: Strategic Outlook
  • Table 94 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Johnson & Johnson Services, Inc.: Product Benchmarking
  • Table 96 Johnson & Johnson Services, Inc.: Strategic Outlook
  • Table 97 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 GSK plc: Product Benchmarking
  • Table 99 GSK plc: Strategic Outlook
  • Table 100 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 Gilead Sciences, Inc.: Product Benchmarking
  • Table 102 Gilead Sciences, Inc.: Strategic Outlook
  • Table 103 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 104 Amgen Inc.: Product Benchmarking
  • Table 105 Amgen Inc.: Strategic Outlook
  • Table 106 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 107 AbbVie Inc.: Product Benchmarking
  • Table 108 AbbVie Inc.: Strategic Outlook
  • Table 109 Immunocore Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 110 Immunocore Ltd.: Product Benchmarking
  • Table 111 Immunocore Ltd.: Strategic Outlook
  • Table 112 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Sanofi: Product Benchmarking
  • Table 114 Sanofi: Strategic Outlook
  • Table 115 Takeda Pharmaceutical Company Limited.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 Takeda Pharmaceutical Company Limited.: Product Benchmarking
  • Table 117 Takeda Pharmaceutical Company Limited.: Strategic Outlook

List of Figures

  • Figure 1 Cancer Immunotherapy Market Segmentation
  • Figure 2 Cancer Immunotherapy Market Attractiveness Index by Region
  • Figure 3 Cancer Immunotherapy Market by Technology: Market Attractiveness Index
  • Figure 4 Cancer Immunotherapy Market by Application: Market Attractiveness Index
  • Figure 5 Cancer Immunotherapy Market by End-users: Market Attractiveness Index
  • Figure 6 Cancer Immunotherapy Market: Market Dynamics
  • Figure 7 Cancer Immunotherapy Market: Impact Analysis
  • Figure 8 Cancer Immunotherapy Industry: Supply Chain Analysis
  • Figure 9 Cancer Immunotherapy Market: Porter's Five Forces Analysis
  • Figure 10 Cancer Immunotherapy Market: PEST Analysis
  • Figure 11 Cancer Immunotherapy Market by Technology: Market Attractiveness Index
  • Figure 12 Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %)
  • Figure 13 Cancer Immunotherapy Market Share Forecast by Technology, 2024, 2029, 2034 (%)
  • Figure 14 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 15 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 16 Immunomodulators Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 17 Immunomodulators Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 18 Other Technology Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 19 Other Technology Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 20 Cancer Immunotherapy Market by Application: Market Attractiveness Index
  • Figure 21 Cancer Immunotherapy Market by Application, 2024-2034 (US$ Billion)
  • Figure 22 Cancer Immunotherapy Market Share Forecast by Application, 2024, 2029, 2034 (%)
  • Figure 23 Lung Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 24 Lung Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 25 Breast Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 26 Breast Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 27 Colorectal Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 28 Colorectal Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Melanoma Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 30 Melanoma Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Prostate Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 32 Prostate Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 33 Head & Neck Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 34 Head & Neck Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 35 Ovarian Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 36 Ovarian Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 37 Pancreatic Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 38 Pancreatic Cancer Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 39 Others Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 40 Others Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 41 Cancer Immunotherapy Market by End-users: Market Attractiveness Index
  • Figure 42 Cancer Immunotherapy Market by End-users, 2024-2034 (US$ Billion)
  • Figure 43 Cancer Immunotherapy Market Share by End-users, 2024, 2029, 2034 (%)
  • Figure 44 Hospitals Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 45 Hospitals Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 46 Cancer Research Centers Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 47 Cancer Research Centers Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 48 Clinics Market Forecast by Region, 2024-2034 (US$ Billion)
  • Figure 49 Clinics Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 50 Cancer Immunotherapy Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
  • Figure 51 Cancer Immunotherapy Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 52 Cancer Immunotherapy Market by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 53 North America Cancer Immunotherapy Market Attractiveness Index
  • Figure 54 North America Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 55 North America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 56 North America Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 57 North America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion, AGR %)
  • Figure 58 North America Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 59 North America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
  • Figure 60 North America Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 61 North America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 62 North America Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 63 U.S. Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 64 Canada Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 65 Europe Cancer Immunotherapy Market Attractiveness Index
  • Figure 66 Europe Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • Figure 67 Europe Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 68 Europe Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 69 Europe Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
  • Figure 70 Europe Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 71 Europe Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
  • Figure 72 Europe Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 73 Europe Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
  • Figure 74 Europe Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034(%)
  • Figure 75 Germany Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 76 UK Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 77 France Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 78 Italy Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 79 Spain Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 80 Switzerland Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 81 Netherlands Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 82 Rest of Europe Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 83 Asia Pacific Cancer Immunotherapy Market Attractiveness Index
  • Figure 84 Asia Pacific Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 85 Asia Pacific Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 86 Asia Pacific Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 87 Asia Pacific Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
  • Figure 88 Asia Pacific Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 89 Asia Pacific Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
  • Figure 90 Asia Pacific Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 91 Asia Pacific Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
  • Figure 92 Asia Pacific Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 93 Japan Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 94 China Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 95 India Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 96 Australia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 97 South Korea Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 98 South East Asia Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 99 Rest of Asia Pacific Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 100 Latin America Cancer Immunotherapy Market Attractiveness Index
  • Figure 101 Latin America Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 102 Latin America Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 103 Latin America Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 104 Latin America Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
  • Figure 105 Latin America Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 106 Latin America Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
  • Figure 107 Latin America Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 108 Latin America Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
  • Figure 109 Latin America Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 110 Brazil Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 111 Mexico Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 112 Argentina Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 113 Rest of Latin America Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 114 MEA Cancer Immunotherapy Market Attractiveness Index
  • Figure 115 MEA Cancer Immunotherapy Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 116 MEA Cancer Immunotherapy Market Forecast by Country, 2024-2034 (US$ Billion)
  • Figure 117 MEA Cancer Immunotherapy Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 118 MEA Cancer Immunotherapy Market Forecast by Technology, 2024-2034 (US$ Billion)
  • Figure 119 MEA Cancer Immunotherapy Market Share Forecast by Technology, 2024 & 2034 (%)
  • Figure 120 MEA Cancer Immunotherapy Market Forecast by Application, 2024-2034 (US$ Billion)
  • Figure 121 MEA Cancer Immunotherapy Market Share Forecast by Application, 2024 & 2034 (%)
  • Figure 122 MEA Cancer Immunotherapy Market Forecast by End-users, 2024-2034 (US$ Billion)
  • Figure 123 MEA Cancer Immunotherapy Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 124 GCC Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 125 South Africa Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 126 Egypt Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 127 Rest of MEA Cancer Immunotherapy Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 128 Cancer Immunotherapy Market: Company Share/Ranking, 2023
  • Figure 129 F. Hoffmann-La Roche Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 130 F. Hoffmann-La Roche Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 131 F. Hoffmann-La Roche Ltd.: Segment Market Shares, 2023
  • Figure 132 F. Hoffmann-La Roche Ltd. Inc.: Regional Market Shares, 2023
  • Figure 133 Merck & Co., Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 134 Merck & Co., Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 135 Merck & Co., Inc.: Segment Market Shares, 2023
  • Figure 136 Merck & Co., Inc.: Regional Market Shares, 2023
  • Figure 137 Novartis AG: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 138 Novartis AG: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 139 Novartis AG: Segment Market Shares, 2023
  • Figure 140 Novartis AG: Regional Market Shares, 2023
  • Figure 141 Bristol-Myers Squibb Company: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 142 Bristol-Myers Squibb Company : R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 143 Bristol-Myers Squibb Company: Segment Market Shares, 2023
  • Figure 144 Bristol-Myers Squibb Company: Regional Market Shares, 2023
  • Figure 145 Bayer AG: Net Revenue, 2019-2023 (US$ Million, AGR (%)
  • Figure 146 Bayer AG: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 147 Bayer AG: Segment Market Shares, 2023
  • Figure 148 Bayer AG: Regional Market Shares, 2023
  • Figure 149 AstraZeneca: Net Revenue, 2019-2023 (US$ Million, AGR (%)
  • Figure 150 AstraZeneca: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 151 AstraZeneca: Segment Market Shares, 2023
  • Figure 152 AstraZeneca: Regional Market Shares, 2023
  • Figure 153 Lilly: Net Revenue, 2019-2023 (US$ Million, AGR (%)
  • Figure 154 Lilly: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 155 Lilly: Regional Market Shares, 2023
  • Figure 156 Pfizer Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 157 Pfizer Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 158 Pfizer Inc.: Segment Market Shares, 2023
  • Figure 159 Pfizer Inc.: Regional Market Shares, 2023
  • Figure 160 Johnson & Johnson Services, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 161 Johnson & Johnson Services, Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 162 Johnson & Johnson Services, Inc.: Segment Market Shares, 2023
  • Figure 163 Johnson & Johnson Services, Inc.: Regional Market Shares, 2023
  • Figure 164 GSK plc: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 165 GSK plc: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 166 GSK plc: Segment Market Shares, 2023
  • Figure 167 GSK plc: Regional Market Shares, 2023
  • Figure 168 Gilead Sciences, Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 169 Gilead Sciences Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 170 Gilead Sciences, Inc.: Segment Market Shares, 2023
  • Figure 171 Gilead Sciences, Inc.: Regional Market Shares, 2023
  • Figure 172 Amgen Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 173 Amgen Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 174 Amgen Inc.: Regional Market Shares, 2023
  • Figure 175 AbbVie Inc.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 176 AbbVie Inc.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 177 AbbVie Inc.: Segment Market Shares, 2023
  • Figure 178 AbbVie Inc.: Regional Market Shares, 2023
  • Figure 179 Immunocore Ltd.: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 180 Immunocore Ltd.: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 181 Immunocore Ltd.: Regional Market Shares, 2023
  • Figure 182 Sanofi: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 183 Sanofi: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 184 Sanofi: Segment Market Shares, 2023
  • Figure 185 Sanofi: Regional Market Shares, 2023
  • Figure 186 Takeda Pharmaceutical Company Limited: Net Revenue, 2019-2023 (US$ Million, AGR %)
  • Figure 187 Takeda Pharmaceutical Company Limited: R&D, 2019-2023 (US$ Million, AGR %)
  • Figure 188 Takeda Pharmaceutical Company Limited: Segment Market Shares, 2023
  • Figure 189 Takeda Pharmaceutical Company Limited.: Regional Market Shares, 2023
目次
Product Code: PHA1340

The global Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034

The Cancer Immunotherapy Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Cancer and Increasing Research in Cancer Immunotherapy are driving the Market Growth

Cancer is a major cause of death worldwide, accounting for about 20 million new cancer cases and over 9 million deaths in 2022, according to data released by the World Health Organisation in February 2024. By 2040, the American Cancer Society, Inc. projects that the global cancer burden would have increased to over 28 million cases due to present and anticipated population ageing and growth. North America is fourth in terms of cancer deaths and fourth in terms of new cases, whereas China, which has the greatest population in the world, has the highest global proportion of both. The cancer burden may rise in the future due to factors such increased alcohol and tobacco use, poor diet, physical inactivity, and air pollution in many different parts of the world.

Modern cancer treatments, such as those based on immunotherapy, have revolutionised the field in recent years. One such treatment that has greatly excited researchers and oncologists is cancer immunotherapy. Globally, cancer immunotherapy is being used as a treatment for cancer after years of intensive research. For instance, the German biomedical research institute BioMed X and one of the biggest pharmaceutical corporations in Japan, Ono Pharmaceutical Co., Ltd., announced in December 2023 the commencement of a new cooperative research initiative. Using neutrophils' anticancer properties to create next-generation immunotherapies is the aim of this research endeavour. Therefore, the primary driver propelling the growth of this market is the ongoing research into how to improve immunotherapy and the ongoing development of novel immunotherapies for the treatment of cancer.

Reimbursement Challenges, High Cost and Side-effects may Hamper Cancer Immunotherapy Growth

Healthcare providers, insurance companies, and national and local government organisations all around the world have faced difficulties in getting reimbursement for cancer immunotherapy treatments. Cancer immunotherapy is one of the priciest medications available, costing more than $100,000 per patient. This covers the price of medications, hospital stays, and multiple days of intensive care because many patients receiving cancer immunotherapy treatments have serious adverse effects.

The Keytruda maker, Merck, states that the out-of-pocket expenses for each infusion might vary from $1,000 to $1,950. However, this rate can still be excessively expensive for many patients. In the event that the patient has Medigap or Medicare Advantage (Part C), additional coverage may be obtained. The Keytruda treatment may potentially be completely covered, depending on the plan. In actuality, 41% of patients with Medicare Advantage Plans reported having no out-of-pocket costs, according to Merck. Patients in developing nations cannot afford the high cost of immunotherapy medications. One of the main obstacles facing businesses developing immunotherapy medications is high pricing. Thus, it is one of the main factors impeding this market's growth over the predicted period.

What Questions Should You Ask Before Buying a Market Research Report?

How is the cancer immunotherapy market evolving?

What is driving and restraining the cancer immunotherapy market?

How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each cancer immunotherapy submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading cancer immunotherapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the cancer immunotherapy projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of cancer immunotherapy projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the cancer immunotherapy market?

Where is the cancer immunotherapy market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Cancer Immunotherapy market today, and over the next 10 years:

Our 286-page report provides 117 tables, 189 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), impact of rising Cancer Immunotherapy prices and recent developments.

Segments Covered in the Report

Technology

Monoclonal Antibodies

Immunomodulators

Other Technology

Application

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Prostate Cancer

Head & Neck Cancer

Ovarian Cancer

Pancreatic Cancer

Others

End-users

Hospitals

Cancer Research Centres

Clinics

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Switzerland

Netherlands

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

South East Asia

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

MEA

GCC

South Africa

Egypt

Rest of MEA

The report also includes profiles for some of the leading companies in the Cancer Immunotherapy Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

Amgen Inc.

AstraZeneca

Bayer AG

Bristol-Myers Squibb Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GSK plc

Immunocore Ltd.

Johnson & Johnson Services, Inc.

Lilly

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Sanofi

Takeda Pharmaceutical Company Limited

Overall world revenue for Cancer Immunotherapy Market, 2024 to 2034 in terms of value the market will surpass US$135.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Cancer Immunotherapy Market, 2024 to 2034 report help you?

In summary, our 280+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Cancer Immunotherapy Market, 2024 to 2034, with forecasts for technology, application, end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 25 key national markets - See forecasts for the Cancer Immunotherapy Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the Cancer Immunotherapy Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Cancer Immunotherapy Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Cancer Immunotherapy Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Increasing Prevalence of Cancer
      • 3.3.1.2 Increasing Research in Cancer Immunotherapy
      • 3.3.1.3 Increasing Funding for the Cancer Research by Government, Public and Private Sector
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Reimbursement Challenges for Cancer immunotherapy
      • 3.3.2.2 High Cost and Side-effects of Cancer Immunotherapy
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Increased Focus towards Advanced Treatment Protocols
      • 3.3.3.2 Significant Unmet Need in Cancer Diagnosis
      • 3.3.3.3 Growing use of AI in Cancer immunotherapy Manufacturing
  • 3.4 Supply Chain Analysis
  • 3.5 Regulatory Framework
  • 3.6 Emerging Markets and Megatrends
  • 3.7 Porter's Five Forces Analysis
    • 3.7.1 Bargaining Power of Buyers (High)
    • 3.7.2 Bargaining Power of Suppliers (Low)
    • 3.7.3 Threat of New Entrants (Low)
    • 3.7.4 Threat of Substitute Products (High)
    • 3.7.5 Intensity of Competitive Rivalry (High)
  • 3.8 PEST Analysis

4 Cancer Immunotherapy Market Analysis by Technology

  • 4.1 Key Findings
  • 4.2 Technology Segment: Market Attractiveness Index
  • 4.3 Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 4.4 Monoclonal Antibodies
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Immunomodulators
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Other Technology
    • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Cancer Immunotherapy Market by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 Cancer Immunotherapy Market, by Application
  • 5.4 Lung Cancer
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Breast Cancer
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Colorectal Cancer
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Melanoma
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Prostate Cancer
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Head & Neck Cancer
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)
  • 5.10 Ovarian Cancer
    • 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.10.2 Market Share by Region, 2024 & 2034 (%)
  • 5.11 Pancreatic Cancer
    • 5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.11.2 Market Share by Region, 2024 & 2034 (%)
  • 5.12 Others
    • 5.12.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.12.2 Market Share by Region, 2024 & 2034 (%)

6 Cancer Immunotherapy Market by End-users

  • 6.1 Key Findings
  • 6.2 End-users Segment: Market Attractiveness Index
  • 6.3 Cancer Immunotherapy Market by End-users Forecast, 2024-2034
  • 6.4 Hospitals
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Cancer Research Centers
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Clinics
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)

7 Cancer Immunotherapy Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America Cancer Immunotherapy Market Analysis

  • 8.1 Key Findings
  • 8.2 North America Cancer Immunotherapy Market Attractiveness Index
  • 8.3 North America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 8.4 North America Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 8.5 North America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 8.6 North America Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 8.7 North America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 8.8 U.S. Cancer Immunotherapy Market Analysis
  • 8.9 Canada Cancer Immunotherapy Market Analysis

9 Europe Cancer Immunotherapy Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe Cancer Immunotherapy Market Attractiveness Index
  • 9.3 Europe Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 9.5 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 9.6 Europe Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 9.7 Europe Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 9.8 Germany Cancer Immunotherapy Market Analysis
  • 9.9 UK Cancer Immunotherapy Market Analysis
  • 9.10 France Cancer Immunotherapy Market Analysis
  • 9.11 Italy Cancer Immunotherapy Market Analysis
  • 9.12 Spain Cancer Immunotherapy Market Analysis
  • 9.13 Switzerland Cancer Immunotherapy Market Analysis
  • 9.14 Netherlands Cancer Immunotherapy Market Analysis
  • 9.15 Rest of Europe Cancer Immunotherapy Market Analysis

10 Asia Pacific Cancer Immunotherapy Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific Cancer Immunotherapy Market Attractiveness Index
  • 10.3 Asia Pacific Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 10.6 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 10.7 Asia Pacific Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 10.8 Japan Cancer Immunotherapy Market Analysis
  • 10.9 China Cancer Immunotherapy Market Analysis
  • 10.10 India Cancer Immunotherapy Market Analysis
  • 10.11 Australia Cancer Immunotherapy Market Analysis
  • 10.12 South Korea Cancer Immunotherapy Market Analysis
  • 10.13 South East Asia Cancer Immunotherapy Market Analysis
  • 10.14 Rest of Asia Pacific Cancer Immunotherapy Market Analysis

11 Latin America Cancer Immunotherapy Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America Cancer Immunotherapy Market Attractiveness Index
  • 11.3 Latin America Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 11.5 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 11.6 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 11.7 Latin America Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 11.8 Brazil Cancer Immunotherapy Market Analysis
  • 11.9 Mexico Cancer Immunotherapy Market Analysis
  • 11.10 Argentina Cancer Immunotherapy Market Analysis
  • 11.11 Rest of Latin America Cancer Immunotherapy Market Analysis

12 MEA Cancer Immunotherapy Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA Cancer Immunotherapy Market Attractiveness Index
  • 12.3 MEA Cancer Immunotherapy Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Country
  • 12.5 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Technology
  • 12.6 MEA Cancer Immunotherapy Market Size Estimation and Forecast by Application
  • 12.7 MEA Cancer Immunotherapy Market Size Estimation and Forecast by End-users
  • 12.8 GCC Cancer Immunotherapy Market Analysis
  • 12.9 South Africa Cancer Immunotherapy Market Analysis
  • 12.10 Egypt Cancer Immunotherapy Market Analysis
  • 12.11 Rest of MEA Cancer Immunotherapy Market Analysis

13 Company Profiles

  • 13.1 Competitive Landscape, 2023
  • 13.2 Strategic Outlook
  • 13.3 F. Hoffmann-La Roche Ltd.
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2019-2023
      • 13.3.3.2 R&D, 2019-2023
      • 13.3.3.3 Segment Market Shares, 2023
      • 13.3.3.4 Regional Market Shares, 2023
    • 13.3.4 Product Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 Merck & Co., Inc.
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Financial Analysis
      • 13.4.3.1 Net Revenue, 2019-2023
      • 13.4.3.2 R&D, 2019-2023
      • 13.4.3.3 Segment Market Shares, 2023
      • 13.4.3.4 Regional Market Shares, 2023
    • 13.4.4 Product Benchmarking
    • 13.4.5 Strategic Outlook
  • 13.5 Novartis AG
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Financial Analysis
      • 13.5.3.1 Net Revenue, 2019-2023
      • 13.5.3.2 R&D, 2019-2023
      • 13.5.3.3 Segment Market Shares, 2023
      • 13.5.3.4 Regional Market Shares, 2023
    • 13.5.4 Product Benchmarking
    • 13.5.5 Strategic Outlook
  • 13.6 Bristol-Myers Squibb Company
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Financial Analysis
      • 13.6.3.1 Net Revenue, 2019-2023
      • 13.6.3.2 R&D, 2019-2023
      • 13.6.3.3 Segment Market Shares, 2023
      • 13.6.3.4 Regional Market Shares, 2023
    • 13.6.4 Product Benchmarking
    • 13.6.5 Strategic Outlook
  • 13.7 Bayer AG
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Financial Analysis
      • 13.7.3.1 Net Revenue, 2019-2023
      • 13.7.3.2 R&D, 2019-2023
      • 13.7.3.3 Segment Market Shares, 2023
      • 13.7.3.4 Regional Market Shares, 2023
    • 13.7.4 Product Benchmarking
    • 13.7.5 Strategic Outlook
  • 13.8 AstraZeneca
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Financial Analysis
      • 13.8.3.1 Net Revenue, 2019-2023
      • 13.8.3.2 R&D, 2019-2023
      • 13.8.3.3 Segment Market Shares, 2023
      • 13.8.3.4 Regional Market Shares, 2023
    • 13.8.4 Product Benchmarking
    • 13.8.5 Strategic Outlook
  • 13.9 Lilly
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Financial Analysis
      • 13.9.3.1 Net Revenue, 2019-2023
      • 13.9.3.2 R&D, 2019-2023
      • 13.9.3.3 Regional Market Shares, 2023
    • 13.9.4 Product Benchmarking
    • 13.9.5 Strategic Outlook
  • 13.10 Pfizer Inc.
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2019-2023
      • 13.10.3.2 R&D, 2019-2023
      • 13.10.3.3 Segment Market Shares, 2023
      • 13.10.3.4 Regional Market Shares, 2023
    • 13.10.4 Product Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 Johnson & Johnson Services, Inc.
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2019-2023
      • 13.11.3.2 R&D, 2019-2023
      • 13.11.3.3 Segment Market Shares, 2023
      • 13.11.3.4 Regional Market Shares, 2023
    • 13.11.4 Product Benchmarking
    • 13.11.5 Strategic Outlook
  • 13.12 GSK plc
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Financial Analysis
      • 13.12.3.1 Net Revenue, 2019-2023
      • 13.12.3.2 R&D, 2019-2023
      • 13.12.3.3 Segment Market Shares, 2023
      • 13.12.3.4 Regional Market Shares, 2023
    • 13.12.4 Product Benchmarking
    • 13.12.5 Strategic Outlook
  • 13.13 Gilead Sciences, Inc.
    • 13.13.1 Company Snapshot
    • 13.13.2 Company Overview
    • 13.13.3 Financial Analysis
      • 13.13.3.1 Net Revenue, 2019-2023
      • 13.13.3.2 R&D, 2019-2023
      • 13.13.3.3 Segment Market Shares, 2023
      • 13.13.3.4 Regional Market Shares, 2023
    • 13.13.4 Product Benchmarking
    • 13.13.5 Strategic Outlook
  • 13.14 Amgen Inc.
    • 13.14.1 Company Snapshot
    • 13.14.2 Company Overview
    • 13.14.3 Financial Analysis
      • 13.14.3.1 Net Revenue, 2019-2023
      • 13.14.3.2 R&D, 2019-2023
      • 13.14.3.3 Regional Market Shares, 2023
    • 13.14.4 Product Benchmarking
    • 13.14.5 Strategic Outlook
  • 13.15 AbbVie Inc.
    • 13.15.1 Company Snapshot
    • 13.15.2 Company Overview
    • 13.15.3 Financial Analysis
      • 13.15.3.1 Net Revenue, 2019-2023
      • 13.15.3.2 R&D, 2019-2023
      • 13.15.3.3 Segment Market Shares, 2023
      • 13.15.3.4 Regional Market Shares, 2023
    • 13.15.4 Product Benchmarking
    • 13.15.5 Strategic Outlook
  • 13.16 Immunocore Ltd.
    • 13.16.1 Company Snapshot
    • 13.16.2 Company Overview
    • 13.16.3 Financial Analysis
      • 13.16.3.1 Net Revenue, 2019-2023
      • 13.16.3.2 R&D, 2019-2023
      • 13.16.3.3 Regional Market Shares, 2023
    • 13.16.4 Product Benchmarking
    • 13.16.5 Strategic Outlook
  • 13.17 Sanofi
    • 13.17.1 Company Snapshot
    • 13.17.2 Company Overview
    • 13.17.3 Financial Analysis
      • 13.17.3.1 Net Revenue, 2019-2023
      • 13.17.3.2 R&D, 2019-2023
      • 13.17.3.3 Segment Market Shares, 2023
      • 13.17.3.4 Regional Market Shares, 2023
    • 13.17.4 Product Benchmarking
    • 13.17.5 Strategic Outlook
  • 13.18 Takeda Pharmaceutical Company Limited.
    • 13.18.1 Company Snapshot
    • 13.18.2 Company Overview
    • 13.18.3 Financial Analysis
      • 13.18.3.1 Net Revenue, 2019-2023
      • 13.18.3.2 R&D, 2019-2023
      • 13.18.3.3 Segment Market Shares, 2023
      • 13.18.3.4 Regional Market Shares, 2023
    • 13.18.4 Product Benchmarking
    • 13.18.5 Strategic Outlook

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from Visiongain
  • 14.2 Recommendations for Market Players